Long Beach, CA Clinical Trials

A listing of Long Beach, CA clinical trials actively recruiting patient volunteers.

Search by Name
Search
Filter by Condition
246 trials found

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

NCT04920786

This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.

Conditions: Alzheimer Disease

Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder

NCT04819776

The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.

Conditions: Bipolar I Disorder

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

NCT04804033

The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.

Conditions: Migraine
Phase: Phase 2/3

A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder

NCT04777357

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associate ...

Conditions: Depression, Bipolar I Disorder

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

NCT04777409

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 ...

Conditions: Early Alzheimer´s Disease

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

NCT04777396

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 ...

Conditions: Early Alzheimer's Disease

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

NCT04770220

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.

Conditions: Early Alzheimer's Disease

Mobile Cardiac Telemetry and Advanced Multi-Parameter Monitoring in Patients

NCT04754204

To determine the associations among biometric data, arrhythmias, subject-reported symptoms and subject wellness.

Conditions: Cardiac Arrhythmia

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

NCT04723394

This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.

Conditions: COVID-19

Prospective US Radiofrequency SUI Trial

NCT04720352

PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pa ...

Conditions: Urinary Incontinence, Stress
Phase: Not Applicable

Placebo-controlled Efficacy and Safety Study of GSK3511294 in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04719832

GSK3511294 is being developed as a long-acting (LA) injectable anti-interleukin-5 (anti-IL-5) therapy and is expected to deliver an efficacy and safety profile similar to current anti-IL-5 therapies with a reduced dosing frequency. This study is a multi-center, randomized, placebo-controlled, double-blind, parallel group design and aims to assess the efficacy and safety of GSK3511294 in participants with severe uncontrolled asthma with an eosinophilic phenotype despite standard of care (SoC) tre ...

Conditions: Asthma

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia

NCT04709224

This is an open-label study to determine the pharmacokinetics, safety and tolerability of single ascending doses of lumateperone long-acting injectable formulation in patients with schizophrenia. Patients will be enrolled in one of up to three cohorts. All patients will receive oral lumateperone for 5 days, followed by a 5-day washout of oral lumateperone, then followed by a single dose of lumateperone LAI.

Conditions: Schizophrenia